Randomized Noninferiority Trial of Reduced High-Dose Volume Versus Standard Volume Radiation Therapy for Muscle-Invasive Bladder Cancer: Results of the BC2001 Trial (CRUK/01/004)

Purpose To test whether reducing radiation dose to uninvolved bladder while maintaining dose to the tumor would reduce side effects without impairing local control in the treatment of muscle-invasive bladder cancer. Methods and Materials In this phase III multicenter trial, 219 patients were randomized to standard whole-bladder radiation therapy (sRT) or reduced high-dose volume radiation therapy (RHDVRT) that aimed to deliver full radiation dose to the tumor and 80% of maximum dose to the uninvolved bladder. Participants were also randomly assigned to receive radiation therapy alone or radiation therapy plus chemotherapy in a partial 2 × 2 factorial design. The primary endpoints for the radiation therapy volume comparison were late toxicity and time to locoregional recurrence (with a noninferiority margin of 10% at 2 years). Results Overall incidence of late toxicity was less than predicted, with a cumulative 2-year Radiation Therapy Oncology Group grade 3/4 toxicity rate of 13% (95% confidence interval 8%, 20%) and no statistically significant differences between groups. The difference in 2-year locoregional recurrence free rate (RHDVRT − sRT) was 6.4% (95% confidence interval −7.3%, 16.8%) under an intention to treat analysis and 2.6% (−12.8%, 14.6%) in the “per-protocol” population. Conclusions In this study RHDVRT did not result in a statistically significant reduction in late side effects compared with sRT, and noninferiority of locoregional control could not be concluded formally. However, overall low rates of clinically significant toxicity combined with low rates of invasive bladder cancer relapse confirm that (chemo)radiation therapy is a valid option for the treatment of muscle-invasive bladder cancer.

• Publication year

  2013

• Venue

  International Journal of Radiation Oncology, Biology, Physics

• Publication date

  2013-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.ijrobp.2013.06.2044PMID 23958147PMCID 3753507
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer.

  2012cited by this paper
• Clinical Investigation : Genitourinary Cancer Whole-Pelvis or Bladder-Only Chemoradiation for Lymph Node e Negative Invasive Bladder Cancer : Single-Institution Experience

  2012cited by this paper
• Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience.

  2012cited by this paper
• TNM Classification of Malignant Tumours, 7th Edition

  2009cited by this paper
• Improving radiotherapy for bladder cancer: an opportunity to integrate new technologies.

  2009cited by this paper
• Late pelvic toxicity after bladder-sparing therapy in patients with invasive bladder cancer: RTOG 89-03, 95-06, 97-06, 99-06.

  2009cited by this paper
• 2043 Defining bowel dose constraints for bladder radiotherapy: using data from patients entered into phase III randomised trial

  2009cited by this paper
• Evaluating the effect of reducing the high-dose volume on the toxicity of radiotherapy in the treatment of bladder cancer.

  2006cited by this paper
• Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results.

  2002cited by this paper
• Radiotherapy for muscle-invasive carcinoma of the bladder: results of a randomized trial comparing conventional whole bladder with dose-escalated partial bladder radiotherapy.

  2002cited by this paper
• Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients.

  2001cited by this paper
• A phase I-II study of synchronous chemoradiotherapy for poor prognosis locally advanced bladder cancer.

  2001cited by this paper
• Long–Term Risk of Salvage Cystectomy after Radiotherapy for Muscle–Invasive Bladder Cancer

  2000cited by this paper
• TNM classification of malignant tumors, fifth edition (1997)

  1997cited by this paper
• Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC)

  1995cited by this paper
• RTOG Late Effects Working Group. Overview. Late Effects of Normal Tissues (LENT) scoring system.

  1995cited by this paper
• Tolerance of normal tissue to therapeutic irradiation.

  1991cited by this paper
• Carcinoma of the urinary bladder category T2,3NXM0 treated by 40 Gy external irradiation followed by cesium137 implant at reduced dose (50%).

  1989cited by this paper
• Radical radiotherapy for muscle invasive transitional cell carcinoma of the bladder: failure analysis.

  1989cited by this paper
• Carcinoma of the urinary bladder category T2,3NXM0 treated by 40 Gy external irradiation followed by cesium137 implant at reduced dose (50%).

  1989cited by this paper
• The results of a series of 963 patients with transitional cell carcinoma of the urinary bladder primarily treated by radical megavoltage X-ray therapy.

  1986cited by this paper

• Prognostic Utility of ctDNA for Trimodality Therapy Outcomes in Muscle Invasive Bladder Cancer

  2026cites this paper
• Radiation Therapy for Anal Squamous Cell Carcinoma: An ASTRO Clinical Practice Guideline.

  2025cites this paper
• Blasenerhaltende multimodale Therapiekonzepte

  2025cites this paper
• Multiparametric MRI and artificial intelligence in predicting and monitoring treatment response in bladder cancer

  2025cites this paper
• Organerhaltende Therapie des muskelinvasiven Harnblasenkarzinoms

  2025cites this paper
• Bladder Preservation Strategies in Muscle-invasive Bladder Cancer: Recommendations from the International Bladder Cancer Group.

  2025cites this paper
• Early Experience Comparing Reduced Planning Target Volume Margins Using Cone Beam Computed Tomography Scan Guided Online Adaptive Radiation Therapy to Nonadaptive, Traditional Margin Plans for Muscle-Invasive Bladder Cancer

  2025cites this paper
• Reduction of the planning target volume with daily online adaptive radiotherapy in bladder cancer

  2025influential citation
• Bladder tumour focused adaptive radiotherapy: Clinical outcomes of a phase I dose escalation study.

  2024cites this paper
• Evidence-based clinical recommendations for hypofractionated radiotherapy: exploring efficacy and safety - Part 3. Genitourinary and gynecological cancers

  2024cites this paper
• Advancements in Urothelial Cancer Care: Optimizing Treatment for Your Patient.

  2024cites this paper
• Blasenerhaltende multimodale Therapiekonzepte

  2024cites this paper
• Dose-Escalated Radiation Therapy as Primary Treatment for Residual Bladder Cancer After Transurethral Resection

  2024cites this paper
• A hypoxia biomarker does not predict benefit from giving chemotherapy with radiotherapy in the BC2001 randomised controlled trial

  2024cites this paper
• Bladder-Preserving Trimodality Therapy With Capecitabine.

  2024cites this paper
• Iodinated hydrogel as a tissue fiducial marker for image-guided radiation therapy in bladder cancer

  2024cites this paper
• Concomitant Chemotherapy in Trimodal Treatment of Patients with Muscle Invasive Bladder Cancer: A Systematic Review of Prospective Trials.

  2024cites this paper
• Bladder Preservation with Radiation: An Effective Alternative to Radical Cystectomy

  2024cites this paper
• Chemoradiation therapy for Nonmetastatic Muscle-Invasive Bladder Cancer: Still the Only Bladder Preservation Treatment in 2024.

  2024cites this paper
• Dose-escalated Adaptive Radiotherapy for Bladder Cancer: Results of the Phase 2 RAIDER Randomised Controlled Trial.

  2024cites this paper
• Effect of complete transurethral resection on oncologic outcomes after radiation therapy for muscle-invasive bladder cancer.: Transurethral resection in radiation therapy.

  2024cites this paper
• Clinical and dosimetric outcomes of image-guided, dose-painted radiotherapy in muscle invasive bladder cancer

  2023cites this paper
• Hypofractionated Radiation Therapy (Hypo-RT) for the Treatment of Localized Bladder Cancer

  2023cites this paper
• Fractionation versus Adaptation for Compensation of Target Volume Changes during Online Adaptive Radiotherapy for Bladder Cancer: Answers from a Prospective Registry

  2023cites this paper
• MRI-guided Pelvic Radiation Therapy: A Primer for Radiologists.

  2023cites this paper
• Prevention of local symptoms in muscle invasive bladder cancer patients: clinical significance of local radiation therapy

  2023cites this paper
• Traitements de préservation vésicale pour le cancer de vessie : la thérapie trimodale, aperçu des pratiques cliniques en 2023

  2023cites this paper
• Trimodal Therapy Using an MR–guided Radiation Therapy Partial Bladder Tumor Boost in Muscle Invasive Bladder Cancer

  2023cites this paper
• Acute Toxicity of Hypofractionated and Conventionally Fractionated (Chemo)Radiotherapy Regimens for Bladder Cancer: An Exploratory Analysis from the RAIDER Trial.

  2023cites this paper
• Trimodal organ‑preserving treatment of muscle‑invasive bladder cancer

  2023cites this paper
• Combined Modality Bladder-Sparing Therapy for Muscle-Invasive Bladder Cancer: How (Should) We Do It? A Narrative Review

  2023cites this paper
• Differences in Quality of Life and Toxicity for Male and Female Patients following Chemo(radiotherapy) for Bladder Cancer.

  2023cites this paper
• Correlation of Clinician- and Patient-Reported Outcomes in the BC2001 Trial.

  2023cites this paper
• How Small Can We Go? Partial Bladder Radiation Therapy and Brachytherapy.

  2023cites this paper
• [Bladder preservation treatments for bladder cancer: Trimodality therapy, an overview of clinical practices in 2023].

  2023cites this paper
• Radiation-based, multi-modality therapy for elderly patients with muscle-invasive bladder cancer: Utility, Rationale, and Efficacy

  2022cites this paper
• Chemoradiotherapy in Muscle-invasive Bladder Cancer: 10-yr Follow-up of the Phase 3 Randomised Controlled BC2001 Trial.

  2022cites this paper
• Feasibility of tumour-focused adaptive radiotherapy for bladder cancer on the MR-linac

  2022cites this paper
• Guideline on trimodal therapy of bladder cancer (Nevskiy consensus 2021)

  2022cites this paper
• The rate of prostatic involvement in men treated with radical cystectomy for muscle invasive bladder cancer.

  2022cites this paper
• Implications for pelvic lymph node irradiation in definitive chemoradiotherapy of node negative muscle invasive bladder cancer based on predictive factors of clinicopathologic discrepancy

  2022cites this paper
• Mapping Local Failure Following Bladder Radiotherapy According to Dose

  2022cites this paper
• Paving the Road to the Future of Chemoradiotherapy in Muscle-invasive Bladder Cancer: 10-year Follow-up of BC2001.

  2022cites this paper
• Treatment Discontinuation in Patients With Muscle-Invasive Bladder Cancer Undergoing Chemoradiation

  2021cites this paper
• Hypofractionated radiotherapy in locally advanced bladder cancer: an individual patient data meta-analysis of the BC2001 and BCON trials

  2021cites this paper
• MR-Guided Adaptive Radiotherapy for Bladder Cancer

  2021cites this paper
• Surgical challenges and considerations in Tri-modal therapy for muscle invasive bladder cancer.

  2021cites this paper
• Is There a Benefit of Combining Immunotherapy and Radiotherapy in Bladder Cancer?

  2021cites this paper
• Fast progression in non–small cell lung cancer: results from the randomized phase III OAK study evaluating second-line atezolizumab versus docetaxel

  2021cites this paper
• Advancing Radiotherapy for Bladder Cancer: Randomised Phase II Trial of Adaptive Image-guided Standard or Dose-escalated Tumour Boost Radiotherapy (RAIDER).

  2021cites this paper
• What is the Optimal Dose, Fractionation and Volume for Bladder Radiotherapy?

  2021cites this paper
• Contemporary and Emerging Approaches to Bladder-Preserving Trimodality Therapy for Muscle-Invasive Bladder Cancer.

  2021cites this paper
• Image-guided Adaptive Radiotherapy for Bladder Cancer.

  2021cites this paper
• Recommendations for planning and delivery of radical radiotherapy for localized urothelial carcinoma of the bladder.

  2021cites this paper
• Instant Oncology: The BC2001/BCON Meta-Analysis.

  2021cites this paper
• Retrospective evaluation of planning margins for patients undergoing radical radiation therapy treatment for bladder cancer using volumetric modulated arc therapy and cone beam computed tomography

  2021cites this paper
• A retrospective review of the long-term outcomes of online adaptive radiation therapy and conventional radiation therapy for muscle invasive bladder cancer

  2021cites this paper
• Hypofractionation: less is more?

  2021cites this paper
• A practical approach to bladder preservation with hypofractionated radiotherapy for localised muscle-invasive bladder cancer

  2021cites this paper
• A phase II study of neoadjuvant chemotherapy followed by organ preservation in patients with muscle-invasive bladder cancer

  2021cites this paper
• Magnetic-resonance-guided Radiation Therapy With Simultaneous Integrated Boost at Mid-bladder Volume for Bladder Cancer

  2021cites this paper
• The Abscopal Effect: A Review of Pre-Clinical and Clinical Advances

  2021cites this paper
• A Prospective Study of a Resorbable Intravesical Fiducial Marker for Bladder Cancer Radiation Therapy

  2021cites this paper
• The Effect of Tri-Modality Therapy with Bladder Preservation for Selective Muscle-Invasive Bladder Cancer

  2021cites this paper
• Non-surgical treatment of bladder cancer

  2020cites this paper
• Review of Experimental Studies to Improve Radiotherapy Response in Bladder Cancer: Comments and Perspectives

  2020cites this paper
• Protocol for tumour-focused dose-escalated adaptive radiotherapy for the radical treatment of bladder cancer in a multicentre phase II randomised controlled trial (RAIDER): radiotherapy planning and delivery guidance

  2020cites this paper
• Outcomes in Patients with Muscle-invasive Bladder Cancer Treated with Neoadjuvant Chemotherapy Followed by (Chemo)radiotherapy in the BC2001 Trial.

  2020cites this paper
• Outcome of radiotherapy for invasive bladder cancer in older patients - not candidates for or decline cystectomy.

  2020cites this paper
• Executive Summary of the American Radium Society Appropriate Use Criteria for Radiation Treatment of Node-Negative Muscle Invasive Bladder Cancer.

  2020cites this paper
• FROGG patterns of practice survey and consensus recommendations on radiation therapy for MIBC

  2020cites this paper
• Image-Guided Radiotherapy for Pelvic Cancers: A Review of Current Evidence and Clinical Utilisation.

  2020cites this paper
• Feasibility of magnetic resonance guided radiotherapy for the treatment of bladder cancer

  2020cites this paper
• Incidence and outcome of salvage cystectomy after bladder sparing therapy for muscle invasive bladder cancer: a systematic review and meta-analysis

  2020cites this paper
• BioXmark® liquid fiducial markers for image guided radiotherapy in muscle invasive bladder cancer, a safety and performance trial.

  2020cites this paper
• Bladder-sparing protocols in the treatment of muscle-invasive bladder cancer

  2020cites this paper
• Overall survival, disease‐specific survival and local recurrence outcomes in patients with muscle‐invasive bladder cancer treated with external beam radiotherapy and brachytherapy: a systematic review

  2020cites this paper
• Outcomes and profiles of elderly patients receiving definitive radiotherapy for muscle-invasive bladder cancer at a tertiary medical center.

  2020cites this paper
• Where is clinical research for radiotherapy going? Cross-sectional comparison of past and contemporary phase III clinical trials

  2020cites this paper
• Trimodality Therapy for Muscle-Invasive Bladder Cancer: Recent Advances and Unanswered Questions

  2020cites this paper
• BioXmark (R) liquid fiducial markers for image-guided radiotherapy in muscle invasive bladder cancer: a safety and performance trial

  2020cites this paper
• Review of hypo-fractionated radiotherapy for localized muscle invasive bladder cancer.

  2019cites this paper
• Adaptive Radiotherapy for Carcinoma of the Urinary Bladder: Long-term Outcomes With Dose Escalation.

  2019cites this paper
• Radiochemotherapie des Harnblasenkarzinoms

  2019cites this paper
• Formidable Scenarios in Urothelial and Variant Cancers of the Urinary Tract.

  2019cites this paper
• Development of a Prediction Tool for Exclusive Locoregional Recurrence After Radical Cystectomy in Patients With Muscle‐Invasive Bladder Cancer

  2019cites this paper
• High-precision Bladder Cancer Irradiation in the Elderly: Clinical Results for a Plan-of-the-day Integrated Boost Technique with Image Guidance Using Lipiodol Markers.

  2019cites this paper
• Palliative radiation therapy in bladder cancer: a matter of dose, techniques and patients' selection.

  2019cites this paper
• Patient-reported Quality of Life Outcomes in Patients Treated for Muscle-invasive Bladder Cancer with Radiotherapy ± Chemotherapy in the BC2001 Phase III Randomised Controlled Trial

  2019cites this paper
• The Future of Radiotherapy in Bladder Cancer

  2018cites this paper
• RETRACTED: Recommandations françaises du Comité de Cancérologie de l’AFU — Actualisation 2018—2020 : tumeurs de la vessie

  2018cites this paper
• How Histopathologic Tumor Extent and Patterns of Recurrence Data Inform the Development of Radiation Therapy Treatment Volumes in Solid Malignancies.

  2018cites this paper
• Recommandations françaises du Comité de Cancérologie de l’AFU – Actualisation 2018–2020 : tumeurs de la vessie

  2018cites this paper
• Radiation Oncology in the 21st Century: Prospective Randomized Trials That Changed Practice… or Didn’t!

  2018cites this paper
• Trimodal therapy for muscle-invasive bladder cancer

  2018cites this paper
• Practice-changing radiation therapy trials for the treatment of cancer: where are we 150 years after the birth of Marie Curie?

  2018cites this paper
• Bladder Preserving Trimodality Therapy for Muscle-Invasive Bladder Cancer

  2018cites this paper
• Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic cancers.

  2018cites this paper
• 8 - Pianificazione E Somministrazione Del Trattamento Radioterapico.

  2018cites this paper
• Bladder Preservation Therapy: Review of Literature and Future Directions of Trimodal Therapy

  2018cites this paper